p21-activated kinases (Paks) are Cdc42/Rac-activated serine-threonine protein kinases that regulate several key cancer-relevant signaling pathways, such as the Mek/Erk, PI3K/Akt and Wnt/b-catenin signaling pathways. Pak1 is frequently overexpressed and/or hyperactivated in different human cancers, including human breast, ovary, prostate and brain cancer, due to amplification of the PAK1 gene in an 11q13 amplicon. Genetic or pharmacological inactivation of Pak1 has been shown to reduce proliferation of different cancer cells in vitro and reduce tumor progression in vivo. In this work, we examined the roles of Pak1 in cellular and animal models of PAK1-amplified ovarian cancer. We found that inhibition of Pak1 leads to decreased proliferation and migration in PAK1-amplified/overexpressed ovarian cancer cells, and has no effect in cell that lack such amplification/overexpression. Further, we observed that loss of Pak1 function causes 11q13-amplified ovarian cancer cells to arrest in the G2/M phase of the cell cycle. This arrest correlates with activation of p53 and p21 Cip and decreased expression of cyclin B1. These findings suggest that smallmolecule inhibitors of Pak1 may have a therapeutic role in the~25% of ovarian cancers characterized by PAK1 gene amplification.
INTRODUCTION
The p21-activated kinases (Paks) are cytosolic Cdc42/Rac-activated serine-threonine protein kinases that regulate a number of key signal transduction pathways. 1 There are 6 Pak isoforms that can be grouped into 2 families: group I (Pak1-3) and group II (Pak4-6) -based on their sequence homology and on presence of a welldefined auto-inhibitory region in group I but not group II Paks. 2 The Paks act as downstream effectors of the Rho family of small GTPases such as Rac and Cdc42, 3 and have important roles in different cellular processes, including cell proliferation, cell survival, adhesion and migration, and anchorage-independent growth. 1 Pak1 regulates a variety of important signaling pathways, including the Ras/Erk, 4, 5 PI3K/Akt and Wnt/β-catenin pathways. 6, 7 In Ras/Erk signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, 4,5 sites thought to be required for Erk activation. It has been reported that Pak1 is required for activation of Akt, though it is not clear if the catalytic activity of Pak1 is required for this function. 8 Recently, it has also been reported that Pak1 can interact with the Wnt/β-catenin pathway. 6, 7 In this case, Pak1 has been shown to associate with β-catenin and phosphorylate it at S663 and S675. These modifications lead to stabilization and relocalization of β-catenin to the nucleus and subsequent transcriptional activity, including upregulation of Myc and Cyclin D1.
Pak1 has been shown to inhibit apoptosis, and this function is thought to be mediated by direct phosphorylation of BAD via c-Raf, and also by activation of the NFκB pathway. 9, 10 In addition, Pak1 signaling has been identified as a component of the DNA damage response, influencing cellular sensitivity to ionizing radiation. 11 Although activating point mutations in the PAK1 gene have not been reported in human cancer, Pak1 is overexpressed in many malignancies, most often due to chromosomal amplification of genes within the 11q13 region. [12] [13] [14] Pak1 can also be hyperactivated by mutations in upstream regulators such as Rac or its exchange factors. 1 Changes to Pak1 mRNA, protein and/or activity in human malignancies, generally positively correlated with advanced tumor grade and decreased survival. In breast and ovarian cancer, amplification of 11q13 is associated with poor prognosis. 13, 14 Genetic or pharmacologic inhibition of Pak1 has been reported to decrease proliferation and migration in different human cancer cells in vitro and to reduce tumor growth in animal models. Importantly, it has been shown that inhibition or deletion of group I Paks can block transformation by oncogenic forms of Kras, ErbB2 and KSHV in animal models. [15] [16] [17] Several studies of 11q13-amplified cells reported that cells with upregulated Pak1 showed marked sensitivity to Pak1 siRNA. 12, 18 In this study, we first determined the effect of Pak1 knockdown on the growth, motility and signaling of human ovarian cancer cells with and without amplified 11q13. As Pak1 has important scaffolding functions that are independent of its kinase activity, we also used newly described selective Pak small-molecule inhibitors to assess if PAK1-amplified ovarian cancer cells show enhanced sensitivity to such agents. We found that ovarian cancer cells with amplified/overexpressed Pak1 were significantly more sensitive to genetic and pharmacologic inhibition of Pak1 in vitro and in vivo. Thus, the presence of PAK1 amplification might serve as a useful patient selection criterion for designing clinical trials of anti-Pak1 agents.
RESULTS

Pak1 expression in ovarian cancer
To investigate the roles of Pak1 in growth of ovarian cancer cells, several different human ovarian cancer cell lines were evaluated 1 for Pak1 mRNA and protein expression ( Figure 1a and b). Pak1 was expressed almost in all ovarian cancer cell lines, with the exception of ES-2. The highest levels of Pak1 were observed in the OVCAR-3 and OV-90 cell lines, which are known to have an amplification of the 11q13 region. 19 To examine the effect of Pak1 loss in ovarian cancer cell lines, cells with or without the 11q13 amplification were transiently transfected with scrambled, Pak1 or Pak2 specific siRNA, and the cells were then assessed for proliferation and migration. Knockdown of Pak1 was efficient, in accord with our previous studies with this siRNA pool. 6 The proliferation rate was evaluated during 120 h of growth after siRNA transfection and the number of attached cells was measured every hour using an xCELLigence device. Similarly, the migration ability of transfected cells was evaluated hourly for 72 h after transfection.
Pak1 knockdown was accompanied by a decreased rate of proliferation (fivefold to eightfold, P o0.0001; Figure 1b ) and migration ( Figure 1 ) in OV-90 and OVAR-3 cells, which bear an 11q13 amplification, but had no significant effect in SKOV-3 cells, which do not bear this amplification (Figure 1c and d) . In contrast, knockdown of Pak2 had no significant effect in any of these cell lines (Supplementary Figure S1A ).
To investigate the effect of long-term Pak1 downregulation in ovarian cancer cells, we used a doxycycline-inducible short hairpin RNA (shRNA) to reduce Pak1. OVCAR-3, OV-90 and SKOV-3 cells were stably transduced with either empty virus or a virus encoding a Pak1 shRNA construct. Upon addition of doxycycline, shRNAtransduced cells displayed a 75-80% loss of Pak1 protein ( Figure 1f ). Depletion of Pak1 in OVCAR-3 cells resulted in 2.3-fold inhibition of cell proliferation (cyQuant assay, Supplementary Figure S1B ) and reduced cell migration (wound healing assay, Figure 1e ), compared with corresponding cells without doxycycline induction. Similar results were observed in the OV-90 cell line, in which Pak1 inhibition by shRNA caused 3.2-fold inhibition of cell proliferation (Supplementary Figure S1B ) and reduced cell migration (Figure 1e ), whereas Pak1 depletion in SKOV-3 cells did not affect cell proliferation. These results suggest that Pak1 is required for efficient growth and migration of ovarian cancer cells that express high levels of this protein, as in 11q13-amplified ovarian cancer cells.
Molecular mechanisms and pathways affected by Pak1 in ovarian cancer in vitro To assess the mechanism by which Pak1 contributes to cellular proliferation, we investigated the effects of Pak1 loss on cell cycle distribution. The cell cycle distribution of OVCAR-3 cells was analyzed by the incorporation of propidium iodide using a Guava cell cycle assay. These experiments revealed that Pak1-knockdown induced a significant increase in the number of cells in G2/M phase (Figure 2a ). In contrast, Pak1 knockdown had a milder effect on cell cycle in OV-90 cells, characterized by a slightly larger G1 population.
Next, we evaluated levels and activity of proteins that regulate the cell cycle ( Figure 2b ). Knockdown of Pak1 in OVCAR-3 cell line led to upregulation of phospho-ATM, CHK1 and p53. As p53 and its transcriptional target p21 Cip can induce cell cycle arrest in the G2/M phase by impeding transcription of cyclin B1, 20 we assessed cyclin B1 levels by western blot and found that they were decreased (Figure 2a ).
Because Pak1 also regulates expression of genes in the DNA damage response pathway, 11 we examined whether Pak1 knockdown was associated with DNA double strand breaks by monitoring Ser-139 phosphorylation of H2A.X, which is a common marker of such damage. 21, 22 Western blot studies clearly showed upregulation of phospho-H2A.X in Pak1-knockdown OVCAR-3 cells, and, to a lesser extent, in OV90 cells ( Figure 2a ). As shown in Figure 2b , immunofluorescence analysis further confirmed Ser-139 phosphorylation of H2A.X and an increase in the formation of γH2A.X foci in Pak1-knockdown OVCAR-3 cells.
Pak1 loss in OV-90 cells resulted to arrest in G1 phase, and, while we observed slight upregulation in phospho-p53 and p21 protein levels, these changes were not associated with downregulation of cyclin B1. Nevertheless, we found that phosphorylation of BRCA1, which is also involved in DNA damage response, was enhanced. It has been shown that BRCA1 can bind and downregulate pRb1, 23 and we found that Pak1 inhibition in OV-90 cells was associated with downregulation of pRb1 and cyclin D. Thus, in both Pak1-amplified cell lines, Pak1 knockdown had cytostatic effects, but the mechanisms were not identical in OVCAR-3 versus OV-90 cells.
Effects of Pak1 inhibition in vivo
To confirm our in vitro results, the role of Pak1 in tumor growth was evaluated using an OV-90 xenograft model ( Figure 3) . A doxocyclin regulated shRNA to Pak1 was introduced into OV-90 ovarian cancer cells by retroviral transduction. 6 Green fluorescent protein-containing colonies were selected to obtain clones with Pak1 knockdown of 480%.
Six-week-old SCID female mice were injected either with control cells or cells with Pak1 shRNA. After tumor establishment, animals were fed with doxycycline-containing food, and tumor growth was monitored for 21-24 days. Inhibition of Pak1 in OV-90 tumors significantly slowed tumor growth compared with that in control mice (P o0.0001; Figure 3 ). Furthermore, analysis of xenograft tumors by immunohistochemistry revealed a substantial decrease in K i -67-positive tumor cells in Dox-treated tumors expressing shPak1 compared with controls ( Figure 3c ). The proportion of K i -67-positive nuclei was quantified, and the anti-proliferative effect of Pak1-knockdown in vivo was shown to be statistically significant (OV-90 control 59 ± 5%, OV-90 shPak1 46 ± 3%, Po 0.01).
Interestingly, when tested using OVCAR-3 cell line, transduction of the Pak1 hairpin did not reduce tumor growth. However, we found that all tumors recovered from such xenografted animals expressed high levels of Pak1. Similar results with respect to the difficulty of maintaining stable Pak1 knockdown have been reported by Yi et al. 24 Together, these findings show that Pak1 is critically important not only for proliferation of Pak1-overexpressing ovarian cancer cells in vitro but also for tumor growth in vivo.
Effects of Pak1 small-molecule inhibitors
A genetic silencing of Pak1 reduces or eliminates the entire Pak1 protein, we also asked if pharmacologic inhibition of Pak1 kinase activity would have similar effects on the growth of ovarian cancer cells. We used two types of Pak inhibitors: PF3758309, which inhibits both group I and II Paks, 25 and FRAX-597, -716 or -1036, which are specific for group I Paks. 26 As shown in Figure 4 , treatment of ovarian cancer cell lines with these Pak small molecules for 72 h dramatically impaired cellular proliferation. Ovarian cancer cell lines with upregulated Pak1 level (OV-90 and OVCAR-3) were more sensitive for Pak1 inhibition compared with the SKOV-3 cell line (Figure 4 ). We also analyzed an larger series of 11q13 plus and minus ovarian cancer cell lines and found a similar correlation between Pak1 expression levels and sensitivity to FRAX-1036 (Supplementary Figure S2) .
As expected, OVCAR-3 and OV-90 cells treated with Pak1 inhibitors showed significant decrease of phospho-Pak1 level and decreased phosphorylation of Mek and Erk ( Figure 5 ). Interestingly, Pak1 or Pak2 RNAi-mediated knockdown did not lead to significant changes in Mek and Erk phosphorylation (data not shown). These data suggests that Pak1 and Pak2 may share redundant functions with respect to the Mek/Erk signaling pathway. OVCAR-3 cell treated with FRAX-1036 (the most specific Pak inhibitor) showed upregulation of p53 and p21 and downregulation of cyclin B1 ( Figure 5 ), similar to results obtained with Pak1 RNAi-mediated knockdown (Figure 2 ).
Pharmacologic inhibition of Pak1 in vivo
To determine the effect of FRAX-1036 on tumor growth in vivo, we used xenograft model of OV-90, OVCAR-3 and SKOV-3 cell lines.
Tumor progression was monitored twice a week for each animal. Three weeks after injection, animals were enrolled randomly into control (vehicle only) or drug-treated groups (50 mg/kg, oral, once daily) for a period of 14 days. Analysis of the tumor growth for the animals in two groups demonstrated a significantly slower tumor growth rate in FRAX-1036-treated mice compared with control mice for OV-90 and OVCAR-3 xenografts, and had no effect in SKOV-3 xenografts ( Figure 6 ). After 14 days of treatment the animals were sacrificed and the tumors excised and weighed. The FRAX-1036-treated cohort showed significantly lower average tumor weight compared with the control cohort (0.32 g versus 0.97 g, and 0.45 g versus 0.29 g, P = 0.0001 for OV-90 and OVCAR-3, respectively). Taken together, these data demonstrate that FRAX-1036 has a significant anti-proliferative activity against ovarian cancer cells with elevated Pak1 level in vitro and antitumor activity in vivo.
DISCUSSION
About 25% of ovarian cancers are characterized genetically by amplification of chromosomal region 11q13. A number of candidate oncogenes reside in this region and may contribute to the growth, survival, and spread of ovarian cancer cells. It has been shown that 11q13.5 amplification is associated with shorter overall survival in ovarian cancer patients. 27 Recently, one of the genes within this amplicon, RSF1 (also known as HBXAP) was found to be involved in paclitaxel resistance. 27 Other nearby genes, including CCND1, GAB2 and EMSY, have also been suggested to play roles in the genesis and maintenance of ovarian cancer, and it is likely that several genes in the 11q13 amplicon contribute to tumorigenesis. 13 The PAK1 gene, which resides at 11q13.5, has been proposed as a potential oncogenic driver in ovarian cancer and other cancers that contain this amplicon. It has been shown by immunohistochemical staining that Pak1 is overexpressed in more than 50% of ovarian carcinomas 28 and correlated with poor overall survival, but rigorous tests for the contribution of PAK1 to the genesis or maintenance of ovarian cancer are lacking. In addition, it is important to note that there is a strong correlation between PAK1 gene copy number and Pak1 mRNA expression levels. 12, 29 In this study we show that ovarian cancer cell lines with 11q13 amplification and elevated Pak1 levels are more sensitive for Pak1 inhibition either by RNAi-mediated/shRNA-mediated knockdown or by small-molecule inhibitors. Loss of Pak1 in these cells led to decreased proliferation in vivo and in vitro. These observations are in keeping with previous studies showing a crucial role for Pak1 in cancer cell proliferation and survival. Knockdown of Pak1 inhibited the anchorage-dependent 18 and -independent 12 growth of breast cancer cells, the proliferation of NSCLC cancers in vitro and in vivo, 18 colon cancer cell growth in vitro 30 and in vivo, 31 and the growth of gastric cancer cells anchorage-dependently and -independently as well as tumor xenografts. 32 In previous studies, gene amplification or increased protein expression Pak1 has been found to correlate with dependence on this pathway for tumor progression. 12, 18 Pak1 has been shown to phosphorylate Mek1 on serine 298. 33 However, in OVCAR-3 cancer cells, inhibition of cell proliferation induced by knockdown of Pak1 did not correlate with consistent reduction in phosphorylation of Mek or Erk. These results suggest that in these ovarian cancer cells, Pak1 promotes tumor cell proliferation independently of the Raf/Mek/Erk pathway. Remarkably, we found that knockdown of Pak1, but not Pak2, led to G 2 /M cell cycle arrest, accompanied by activation of p53, strongly increased expression of p21 cip , and reduced expression of cyclin B1, consistent with the observed cell cycle effects. These findings were unexpected, as OVCAR-3 cells bear a R248Q mutation in p53 that reduces its ability to bind DNA and activate transcription. 34, 35 We speculate that loss of Pak1 leads to phosphorylation and reactivation of this mutant p53 protein, partly restoring its function through a conformational change. In that regard, it is interesting to note that p53 activation and G2/M arrest has been reported in OVCAR-3 cells in response to treatment with triptolide 36 or TNF-α and IFN-γ. 37 In contrast to OVCAR-3, Pak1 knockdown in OV-90 led to a delay in G1 transit, rather than a G2/M arrest. The p53 S215R mutation in this cell line, like p53 R248Q, is associated with defective transcriptional activity. However, the degree of p53 activation in response to Pak1 knockdown was much less than in OVCAR-3 cells (Figure 2a and c) . Interestingly, in OV-90 cells, Pak1 knockdown was associated with activation of the DNA damage response protein, BRCA1 (Figure 2c ). BRCA1 has several Rb-binding sites 38, 39 and overexpression of wild-type BRCA1 inhibits expression of pRb and pRb family (p107 and p130) proteins. 23 In this work, we confirmed that Pak1 inhibition in OV-90 cells is associated with phospho-BRCA1 upregulation and pRb and cyclin-D downregulation, consistent with the observed G1 delay.
Previously, we reported that treatment of breast cancer mouse xenografts 6 and K-ras-driven skin cancer mouse model with either the pan-Pak inhibitor PF3758309 or the group I-specific Pak inhibitor FRAX-597 decreased tumor growth. 40 In the present study, we investigated FRAX-597, -716 and -1036, a series of increasingly specific group I Pak small-molecule inhibitors. 26 All three group I Pak inhibitors decreased proliferation and survival of the ovarian cancer cells OV-90 and OVCAR-3 in vitro. FRAX-1036, the most specific Pak1 inhibitor, 26 was also effective in inhibiting tumor growth in vivo. These results support earlier studies with Pak inhibitors 41, 42 and, together with our shRNA data, suggest that inhibition of Pak1 could be an effective approach for suppressing the growth of ovarian carcinomas with increased Pak1 expression, such as those characterized by 11q13 amplification.
MATERIALS AND METHODS
Animal experiments
All animal experiments were approved by the Fox Chase Cancer Center Institutional Animal Care and Use Committee and carried out according to the National Institutes of Health-approved protocols in compliance with the guide for the Care and Use of Laboratory Animals.
Statistical analysis
Statistical analysis was conducted using the unpaired Student's t-test. Values of Po 0.05 were considered significant.
Cell lines, cell culture OVAR-3, OV-90 and SKOV-3 cell lines were acquired from the American Type Culture Collection, authenticated, tested for mycoplasma contamination, and maintained in early passages, no more than 6 months after receipt from the American Type Culture Collection. Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in 95% air/5% CO 2 .
Real-time qRT-PCR
The level of PAK1 gene expression was measured using qRT-PCR as previously described. 6 Primers and TaqMan probes for GAPDH and PAK1, and TaqMan master mix were from Applied Biosystems.
Western blot analysis
Following the experimental treatment, western blot analysis were performed as previously described. 6 Immunoblot analyses were carried out on lysates extracted from cells or tumors. Protein concentration was determined, and equal amounts of total proteins were separated on SDS-PAGE. Antibodies used included total (SCT #2602) and phospho-Pak1(SC #2606), Mek (SCT#9121), phospho-Mek pSer298(SCT#9128), Erk (SCT#9102), phospho-Erk1/2 (pThr202/pTyr204) (SCT#9101), phospho-ATM, phospho-ATR, phospho-Chk1, phospho-Chk2, phospho-p53, p21 Cip (SCT DNA damage sampler kit, Cell Signaling Technology, Danvers, MA, USA; #9947), cyclin B(SCT#4128), cyclin D1(SCT#2978), GAPDH (SCT#4138) were from Cell Signaling Technology.
Transient transfection
Cells were plated at a density of 5 × 10 5 cells in six-well dishes and incubated for 4 h. The cells were transiently transfected with siRNA smartpool oligonucleotides (10 nM) targeting Pak1 or Pak2 (Dharmacon, Waltham, MA, USA) using RNAiMax (Invitrogen, Carsbad, CA, USA) according to the manufacturer's instructions. Non-target siRNA was used as a control.
Retroviral transductions
An inducible shRNA-bearing retrovirus against Pak1 was previously described 6 and oligonucleotide used in this study are as follows: Pak1 shRNA-1 5′-GATCCCCGAAGAGAGGTTCAGCTAAATTCAAGAGATTTAGC TGAACCTCTCTTCTTTTTTGGAAA-3′; the ΦNX packaging cell line (Orbigen, San Diego, CA, USA) was transfected using Lipofectamine 2000 (Invitrogen). Viral supernatants were harvested 48 h post-transfection and filtered. Ovarian cancer cells were incubated with retroviral supernatant supplemented with 4 μg/ml polybrene for 4 h at 37°C, and then were cultured in growth media for 48 h for viral integration. Green fluorescent proteinpositive infected cells were selected by flow cytometry.
Cell viability assay
Cells were plated at 4 × 10 3 cells per well in 96-well plates overnight and treated with various concentrations of Pak inhibitors for 72 h. Cell viability was measured by Alamar assay and the half maximal inhibitory concentration (IC 50 ) was calculated.
Cell cycle distribution
For cell cycle profiles, cells were transfected with Pak1 siRNA. Seventy-two hours after transfection cells were collected, washed, and fixed in 70% ethanol. After fixation, cells were resuspended in 0.5 ml of a Guava Cell cycle solution (1 M Tris-HCl pH 8.0, 0.1% Nonidet P-40, 10 mM NaCl, 50 μg/ ml propidium iodide and 70 Kunitz units/mlRNase A). DNA content was analyzed using Guava software (Millipore, Billerica, CA, USA). A minimum of 10 000 events was collected per sample.
Proliferation and migration assays
Cell proliferation was assessed using E-16-well plates and the xCELLigence technology (Acea Bioscience, San Diego, CA, USA, distributed by Roche Diagnostics). 43 Briefly, cells (4 × 10 3 OVCAR-3 cells/well) were transfected with non-target or target siRNA (Dharmacon) with RNAiMax (Invitrogen) using reverse transfection protocol in E-16-well. Cell growth was monitored for 72 h. Microelectrodes, placed on the bottom of plates, were used to detect impedance changes proportional to the number of adherent cells and expressed as the cell index. The impedance value of each well was automatically monitored by the xCELLigence system (Acea Bioscience) and expressed as a cell index value. The experiments were conducted in triplicate and repeated twice.
Cell migration assays were performed using an xCELLigence system (CIM-plates). Cell were transfected (1 × 10 4 in OPTI-MEM medium) with non-target or Pak1 siRNA and cultured for 72 h. About 10 5 cells were seeded in the upper chamber of the CIM-plates in serum-free media. The lower chamber was filled with RPMI-1640 medium containing 10% fetal bovine serum. Cell index as acquired by the software was set to 100% migration after flattening of the slope. Experiments were performed in triplicate. The rate of cell migration was monitored in real-time with the xCELLigence system for duration of 48 h and expressed as a cell index value.
Immunofluorescence analysis
Cells were fixed in 4% paraformaldehyde at room temperature for 15 min, and processed as described. Confocal analyses were performed with a Nikon TE2000 confocal microscopy system (Nikon, Mellville, NY, USA).
Wound-healing assay
Cell monolayers were scratched using a 200-μL pipette tip after the cells had reached 70% confluency in RPMI-1640 medium supplemented with 1% fetal bovine serum. Photomicrographs were then taken at × 100 magnification with an EVOS fluorescence microscope (EVOS).
Tumor xenografts in SCID mice: FRAX-1036 treatment
Six-week-old female SCID mice were injected with 5 × 10 6 OVCAR-3, OV-90 or SKOV-3 cells into the flank, and tumors were allowed to develop. Upon identification of a palpable tumor (minimal volume of 150-200 mm 3 ), mice were randomly divided into 2 groups (10 mice in each group). Vehicle or drug (30 μg/kg body weight) was administered via oral gavage every day for 21 days.
Pak1 stable knockdown
Six-week-old female SCID mice were injected with 5 × 10 6 OV-90 or shPak1-OV-90 cells into the flank, and tumors were allowed to develop. Three weeks after injection mice were randomly divided into 4 groups. Control mice were fed a diet lacking doxycycline, whereas a doxycycline diet was given to a similar number of mice from each cohort.
Tumor length (L) and width (W) were measured with a caliper and tumor volumes were calculated with the formula (L × W 2 )/2. At the end of the treatment period, the animals were euthanized and the tumors were used for biochemical studies.
Tissue preparation, histology, immunohistochemistry
All tumors were fixed overnight in 4% paraformaldehyde, dehydrated and embedded in paraffin. Hematoxylin and eosin stained sections were used for diagnostic purposes and unstained sections for immunohistochemical studies. Immunohistochemical study was conducted with rat monoclonal antibody for Ki67 (Dako). The evaluation of the immunohistochemical was conducted blindly, without knowledge of the origin or genotype. The percentage of Ki67-positive cells was determined by scanning the slides using an Aperio CS Scanscope scanner (Aperio, Vista, CA, USA) and Aperio's image viewer software (ImageScope, version 11.1.2.760, Aperio) (2000-5000 cells were counted per mouse, 3-5 mice/group).
